JP7522095B2 - 原発性ミトコンドリア病のためのミトコンドリア増強療法 - Google Patents

原発性ミトコンドリア病のためのミトコンドリア増強療法 Download PDF

Info

Publication number
JP7522095B2
JP7522095B2 JP2021502844A JP2021502844A JP7522095B2 JP 7522095 B2 JP7522095 B2 JP 7522095B2 JP 2021502844 A JP2021502844 A JP 2021502844A JP 2021502844 A JP2021502844 A JP 2021502844A JP 7522095 B2 JP7522095 B2 JP 7522095B2
Authority
JP
Japan
Prior art keywords
stem cells
mitochondrial
mitochondria
cells
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021502844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531284A (ja
JP2021531284A5 (cg-RX-API-DMAC10.html
Inventor
オハナ，ナタリエ イヴギ
ハラヴィー，ウリエル
ブクスファン，シュムエル
シャー，ノア
ブルムキン，モリヤ
Original Assignee
ミノヴィア セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミノヴィア セラピューティクス リミテッド filed Critical ミノヴィア セラピューティクス リミテッド
Publication of JP2021531284A publication Critical patent/JP2021531284A/ja
Publication of JP2021531284A5 publication Critical patent/JP2021531284A5/ja
Priority to JP2024111826A priority Critical patent/JP2024138460A/ja
Application granted granted Critical
Publication of JP7522095B2 publication Critical patent/JP7522095B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021502844A 2018-07-22 2019-07-22 原発性ミトコンドリア病のためのミトコンドリア増強療法 Active JP7522095B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024111826A JP2024138460A (ja) 2018-07-22 2024-07-11 原発性ミトコンドリア病のためのミトコンドリア増強療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862701783P 2018-07-22 2018-07-22
US62/701,783 2018-07-22
US201862753947P 2018-11-01 2018-11-01
US62/753,947 2018-11-01
PCT/IL2019/050823 WO2020021536A1 (en) 2018-07-22 2019-07-22 Mitochondrial augmentation therapy for primary mitochondrial diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024111826A Division JP2024138460A (ja) 2018-07-22 2024-07-11 原発性ミトコンドリア病のためのミトコンドリア増強療法

Publications (3)

Publication Number Publication Date
JP2021531284A JP2021531284A (ja) 2021-11-18
JP2021531284A5 JP2021531284A5 (cg-RX-API-DMAC10.html) 2022-07-19
JP7522095B2 true JP7522095B2 (ja) 2024-07-24

Family

ID=69181378

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021502844A Active JP7522095B2 (ja) 2018-07-22 2019-07-22 原発性ミトコンドリア病のためのミトコンドリア増強療法
JP2024111826A Pending JP2024138460A (ja) 2018-07-22 2024-07-11 原発性ミトコンドリア病のためのミトコンドリア増強療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024111826A Pending JP2024138460A (ja) 2018-07-22 2024-07-11 原発性ミトコンドリア病のためのミトコンドリア増強療法

Country Status (11)

Country Link
US (1) US12502408B2 (cg-RX-API-DMAC10.html)
EP (1) EP3823647A4 (cg-RX-API-DMAC10.html)
JP (2) JP7522095B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210035212A (cg-RX-API-DMAC10.html)
CN (1) CN112566645A (cg-RX-API-DMAC10.html)
AU (1) AU2019311859B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021001190A2 (cg-RX-API-DMAC10.html)
CA (1) CA3106186A1 (cg-RX-API-DMAC10.html)
IL (1) IL280163B2 (cg-RX-API-DMAC10.html)
MX (1) MX2021000955A (cg-RX-API-DMAC10.html)
WO (1) WO2020021536A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282198B2 (en) 2011-09-11 2025-11-01 Minovia Therapeutics Ltd Compositions of functional mitochondria and uses thereof
JP7524157B2 (ja) 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法
WO2020021535A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of ocular diseases
US12502408B2 (en) 2018-07-22 2025-12-23 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
WO2020021539A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of muscle diseases
US12329781B2 (en) 2018-07-22 2025-06-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
EP3823644A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF PANCREATIC DISEASES
MX2022012157A (es) 2020-03-31 2023-02-15 Minovia Therapeutics Ltd Celulas geneticamente modificadas enriquecidas con mitocondrias y usos de estas.
CN115427052A (zh) * 2020-03-31 2022-12-02 米诺维亚治疗公司 线粒体加强疗法
US20230190822A1 (en) * 2020-05-05 2023-06-22 Pluri Biotech Ltd. Methods and compositions for enrichment of target cells
CN114699430A (zh) * 2022-04-12 2022-07-05 重庆理工大学 线粒体及其在胰腺炎中的应用和应用方法
US20260069634A1 (en) * 2022-04-27 2026-03-12 Paean Biotechnology Inc. Pharmaceutical composition, for preventing or treating hearing loss or tinnitus, comprising mitochondria as active ingredient
KR20250065545A (ko) * 2023-11-03 2025-05-13 서울대학교병원 미토콘드리아를 유효성분으로 포함하는 유전성 난청의 예방 또는 치료용 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017124037A1 (en) 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
JP2018507690A (ja) 2015-02-26 2018-03-22 ミノヴィア セラピューティクス リミテッド 機能性ミトコンドリアで富化された哺乳動物細胞
WO2018101708A1 (ko) 2016-11-30 2018-06-07 차의과학대학교 산학협력단 미토콘드리아를 포함하는 약학 조성물

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9604400A (es) 1994-03-30 1997-12-31 Mitokor Diagnostico, terapia y modelos celular y animal para enfermedades asociadas con defectos mitocondriales.
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
JP2002538167A (ja) 1999-03-03 2002-11-12 バイオジェン インコーポレイテッド 脂質の代謝および貯蔵を調節する方法
GB2350565A (en) 1999-05-28 2000-12-06 Johnson & Johnson Medical Ltd Biological wound dressings comprising mitochondria
DE19937348A1 (de) 1999-08-11 2001-02-22 Aventis Cropscience Gmbh Nukleinsäuremoleküle aus Pflanzen codierend Enzyme, die an der Stärkesynthese beteiligt sind
JP2004500409A (ja) 2000-03-31 2004-01-08 ザ　ジェネラル　ホスピタル　コーポレーション 毛の成長を調節する方法
EP1325743A4 (en) 2000-10-13 2004-12-15 Chugai Pharmaceutical Co Ltd COMPOSITIONS TO IMPROVE FAT METABOLISM
US20030040475A1 (en) 2001-01-16 2003-02-27 Yasuhiro Toba Agents for improving lipid metabolism and reducing high blood pressure
US7339090B2 (en) 2001-02-13 2008-03-04 Avigenics, Inc. Microinjection devices and methods of use
JP4603192B2 (ja) 2001-05-10 2010-12-22 株式会社カネカ 毛髪頭皮用組成物
WO2003012050A2 (en) 2001-07-31 2003-02-13 Northeastern University Mitochondrial genome replenishment
AU2002324645C1 (en) 2001-08-08 2008-11-06 Levesque Biosciences, Inc. Compositions and methods for isolation, propagation, and differentiation of human stem cells and uses thereof
US7138134B2 (en) 2001-12-18 2006-11-21 Arizona Health Consulting Group, Llc Preparation and administration of jojoba product for reducing weight, fat and blood lipid levels
US20050153381A1 (en) 2002-02-14 2005-07-14 Marusich Michael F. Immunocapture of mitochondrial protein complexes
AU2004238375A1 (en) 2003-05-13 2004-11-25 The Regents Of The University Of Colorado Diagnostic and therapeutic treatments related to mitochondrial disorders
WO2004103389A2 (en) 2003-05-22 2004-12-02 Theraptosis Sa Means for preventing and treating cellular death and their biological applications
US7407800B1 (en) 2003-09-19 2008-08-05 Pierce Biotechnology, Inc. Method for the isolation of intact mitochondria from cells
CA2551190A1 (en) 2003-12-23 2005-07-07 Nono Inc. Polypeptides for modulating binding of trp channel proteins and trp-associated proteins.
US20060024277A1 (en) 2004-07-27 2006-02-02 Sivak Hannah N Method of skin care and/or treatment using extracts enriched in mitochondria
JP2006131600A (ja) 2004-11-09 2006-05-25 R & D Cell-Science Optional Medico:Kk 発毛促進のためのヒト細胞組成物
EA035619B1 (ru) 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
EP3417868A1 (en) 2005-06-10 2018-12-26 Thylabisco AB Composition
AU2012201710B2 (en) 2006-05-11 2014-01-16 Regenics As Administration of cells and cellular extracts for rejuvenation
AT502353B1 (de) 2006-06-29 2007-07-15 Avl List Gmbh Verfahren und vorrichtung zur konditionierung eines o2-hältigen gases
CA2688125A1 (en) 2007-05-02 2008-11-13 The Mclean Hospital Corporation Methods and compositions for mitochondrial replacement therapy
WO2008152640A2 (en) 2007-06-13 2008-12-18 Pluristem Ltd. Three dimensional biocompatible scaffolds for ex-vivo expansion and transplantation of stem cells
WO2009154770A2 (en) 2008-06-18 2009-12-23 The Texas A & M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
US20110105359A1 (en) 2009-10-30 2011-05-05 Xenotech, Llc Cryopreservation of cells and subcellular fractions
US8338178B2 (en) 2010-10-28 2012-12-25 The Invention Science Fund I, Llc Mitochondrial enhancement of cells
DK2645993T3 (en) 2010-12-03 2017-02-13 Allergan Inc Pharmaceutical cream compositions comprising oxymetazoline
CN113142581B (zh) 2010-12-23 2025-07-22 阿马曾提斯公司 用于改善线粒体功能的组合物和方法
EP2726601B1 (en) 2011-06-29 2018-12-26 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
US20130022666A1 (en) 2011-07-20 2013-01-24 Anna Brzezinska Methods and compositions for transfer of mitochondria into mammalian cells
CN102266350A (zh) 2011-07-20 2011-12-07 黄必录 逆转干细胞衰老的方案
CN102293178A (zh) 2011-08-28 2011-12-28 黄必录 使个体去衰老的方法
IL282198B2 (en) 2011-09-11 2025-11-01 Minovia Therapeutics Ltd Compositions of functional mitochondria and uses thereof
CN104066837B (zh) 2011-12-02 2020-12-08 菲特治疗公司 增强的干细胞组合物
US8648034B2 (en) 2011-12-09 2014-02-11 Changhua Christian Hospital Method and applications of peptide-mediated mitochondrial delivery system
WO2013149064A1 (en) 2012-03-30 2013-10-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells
US10702556B2 (en) 2012-05-16 2020-07-07 Minovia Therpautices Ltd. Compositions and methods for inducing angiogenesis
WO2014091312A2 (en) 2012-12-10 2014-06-19 Regenics As Use of cellular extracts for skin rejuvenation
ES2860573T3 (es) * 2013-02-19 2021-10-05 Childrens Medical Center Células madre ABCB5(+) para el tratamiento de enfermedades oculares
DE102013225588A1 (de) 2013-12-11 2014-04-17 Henkel Ag & Co. Kgaa Verwendung und Mittel zur Verbesserung der Haarstruktur
KR20240164967A (ko) 2014-02-04 2024-11-21 카이트 파마 인코포레이티드 B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
EP2918458B1 (en) 2014-03-11 2016-12-07 Autoliv Development AB A vehicle braking arrangement
US20170080030A1 (en) 2014-03-17 2017-03-23 University Of Virginia Patent Foundation Compositions and methods for treating retinopathy
CN103976935A (zh) 2014-05-28 2014-08-13 广州市白云区天芳化妆品厂 一种抗衰原液及其制备方法
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
WO2016008937A1 (en) * 2014-07-16 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the intercellular transfer of isolated mitochondria in recipient cells
WO2016037587A1 (en) 2014-09-11 2016-03-17 Taiwan Mitochondrion Applied Technology Co., Ltd Pharmaceutical compositions for treating degenerative neurological disease with mitocells
JP6441472B2 (ja) 2014-09-30 2018-12-19 台灣粒線體應用技術股▲扮▼有限公司Ｔａｉｗａｎ Ｍｉｔｏｃｈｏｎｄｒｉｏｎ Ａｐｐｌｉｅｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ． 活性成分として外因性ミトコンドリアを含む組成物、ならびにその使用およびそのための細胞修復法
EP3219322A4 (en) 2014-11-14 2018-06-20 JCR Pharmaceuticals CO., LTD. Muscular dystrophy therapeutic agent containing pluripotent stem cells derived from dental pulp
GB201500427D0 (en) 2015-01-12 2015-02-25 Isis Innovation Method
WO2016112425A1 (en) 2015-01-14 2016-07-21 Calix Ltd Improved pathogen inhibitor
WO2016115632A1 (en) * 2015-01-21 2016-07-28 Exerkine Corporation Method for treating mitochondrial disease
CA2976776C (en) 2015-02-17 2023-06-20 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
US10537594B2 (en) 2015-02-27 2020-01-21 University Of Connecticut Targeted transplantation of mitochondria to hepatocytes
KR20180019613A (ko) * 2015-05-28 2018-02-26 셀룰래리티, 인코포레이티드 태반-유래 줄기 세포 및 그의 재생 엔진 복구, 프로테옴 결함 수정 및 노화 객체의 수명 연장 용도
US20170151287A1 (en) 2015-11-30 2017-06-01 Flagship Ventures Management, Inc. Methods and compositions of chondrisomes
JP2017105729A (ja) 2015-12-10 2017-06-15 国立大学法人東北大学 ミトコンドリア病の治療剤
AU2017354272A1 (en) 2016-11-03 2019-05-23 Exostem Biotec Ltd. Mesenchymal stem cells populations, their products, and use thereof
WO2018088874A1 (ko) 2016-11-14 2018-05-17 주식회사 파이안바이오테크놀로지 외래 미토콘드리아를 세포로 전달하는 방법
US20200023005A1 (en) 2017-03-26 2020-01-23 Minovia Therapeutics Ltd. Mitochondrial compositions and methods for treatment of skin and hair
WO2020021541A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria
US12502408B2 (en) 2018-07-22 2025-12-23 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
WO2020021537A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of liver diseases
WO2020021539A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of muscle diseases
JP7524157B2 (ja) 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法
WO2020021535A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of ocular diseases
EP3823644A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF PANCREATIC DISEASES
KR20210045435A (ko) 2018-08-14 2021-04-26 이멜 바이오테라퓨틱스, 인코포레이티드. 미토콘드리아 질환 또는 장애 및 헤테로플라스미를 치료하기 위한 방법 및 조성물
CA3138566A1 (en) 2019-04-30 2020-11-05 Larimar Therapeutics, Inc. Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy
MX2022012157A (es) 2020-03-31 2023-02-15 Minovia Therapeutics Ltd Celulas geneticamente modificadas enriquecidas con mitocondrias y usos de estas.
CN115427052A (zh) 2020-03-31 2022-12-02 米诺维亚治疗公司 线粒体加强疗法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507690A (ja) 2015-02-26 2018-03-22 ミノヴィア セラピューティクス リミテッド 機能性ミトコンドリアで富化された哺乳動物細胞
WO2017124037A1 (en) 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
WO2018101708A1 (ko) 2016-11-30 2018-06-07 차의과학대학교 산학협력단 미토콘드리아를 포함하는 약학 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The Champ Foundation, William's blog., Conference Recap，2018年02月15日
The Champ Foundation, William's blog., Let's get MORE research started!，2017年05月01日

Also Published As

Publication number Publication date
WO2020021536A9 (en) 2020-03-05
WO2020021536A1 (en) 2020-01-30
IL280163B2 (en) 2026-01-01
KR20210035212A (ko) 2021-03-31
MX2021000955A (es) 2021-05-27
US20210260137A1 (en) 2021-08-26
CN112566645A (zh) 2021-03-26
JP2021531284A (ja) 2021-11-18
AU2019311859A1 (en) 2021-02-04
CA3106186A1 (en) 2020-01-30
BR112021001190A2 (pt) 2021-04-27
EP3823647A1 (en) 2021-05-26
US12502408B2 (en) 2025-12-23
JP2024138460A (ja) 2024-10-08
IL280163A (en) 2021-03-01
EP3823647A4 (en) 2022-06-01
AU2019311859B2 (en) 2025-12-18
IL280163B1 (en) 2025-09-01

Similar Documents

Publication Publication Date Title
JP2024138460A (ja) 原発性ミトコンドリア病のためのミトコンドリア増強療法
JP7263455B2 (ja) 機能性ミトコンドリアで富化された哺乳動物細胞
US20240415894A1 (en) Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria
US12239672B2 (en) Mitochondrial augmentation therapy of ocular diseases
JP7458368B2 (ja) 筋疾患のミトコンドリア増強療法
US12440515B2 (en) Mitochondrial augmentation therapy of brain diseases
WO2020021540A9 (en) Mitochondrial augmentation therapy of pancreatic diseases
JP2021532095A (ja) 肝臓疾患のミトコンドリア増強療法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240711

R150 Certificate of patent or registration of utility model

Ref document number: 7522095

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150